Fresco: A Phase 2, Randomized Study Of Duvelisib Plus Rituximab Vs R-Chop In Patients With Relapsed/Refractory Follicular Lymphoma Who Have Progressed Within 24 Months Of Receiving An Alkylator-Based Chemotherapy Regimen.
JOURNAL OF CLINICAL ONCOLOGY（2016）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要